Elliott D. Kieff enseignant américain
Kieff, Elliott D., 1943-
Kieff, Elliott D.
VIAF ID: 119820489 (Personal)
Permalink: http://viaf.org/viaf/119820489
Preferred Forms
- 100 0 _ ‡a Elliott D. Kieff ‡c enseignant américain
- 100 1 _ ‡a Kieff, Elliott D
- 100 1 _ ‡a Kieff, Elliott D. (sparse)
- 100 1 _ ‡a Kieff, Elliott D. ‡d 1943-
- 100 1 0 ‡a Kieff, Elliott D., ‡d 1943-
4xx's: Alternate Name Forms (7)
Works
Title | Sources |
---|---|
Abstracts of papers presented at the fourth Cold Spring Harbor ... 1979? | |
Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes | |
An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro | |
Expression of Epstein-Barr virus (EBV) DNA and cloned DNA fragments in human lymphocytes following Sendai virus envelope-mediated gene transfer | |
Expression of the Epstein-Barr virus gp350/220 gene in rodent and primate cells | |
Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell lines | |
Genome-wide analysis reveals conserved and divergent features of Notch1/RBPJ binding in human and murine T-lymphoblastic leukemia cells | |
Genome-wide siRNA screen for mediators of NF-κB activation | |
Herpes viral deoxyribonucleic acid | |
Herpesvirus papio DNA is similar in organization to Epstein-Barr virus DNA | |
Human ubiquitin specific protease 31 is a deubiquitinating enzyme implicated in activation of nuclear factor-kappaB | |
Identification, cloning and characterization of a novel nuclear protein, HA95, homologous to A-kinase anchoring protein 95 | |
Identification of p100 as a coactivator for STAT6 that bridges STAT6 with RNA polymerase II. | |
Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies | |
An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking | |
Interpreting cancer genomes using systematic host network perturbations by tumour virus proteins | |
Intracellular forms of human NOTCH1 interact at distinctly different levels with RBP-jkappa in human B and T cells | |
Intracellular trafficking of two major Epstein-Barr virus glycoproteins, gp350/220 and gp110 | |
IRF7 activation by Epstein-Barr virus latent membrane protein 1 requires localization at activation sites and TRAF6, but not TRAF2 or TRAF3 | |
Latent infection membrane protein transmembrane FWLY is critical for intermolecular interaction, raft localization, and signaling | |
LMP1 association with CD63 in endosomes and secretion via exosomes limits constitutive NF-κB activation | |
LMP1 TRAFficking activates growth and survival pathways | |
LMP1 transmembrane domain 1 and 2 (TM1-2) FWLY mediates intermolecular interactions with TM3-6 to activate NF-kappaB | |
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development | |
Mapping of polypeptides encoded by the Epstein-Barr virus genome in productive infection | |
Marker rescue of a transformation-negative Epstein-Barr virus recombinant from an infected Burkitt lymphoma cell line: a method useful for analysis of genes essential for transformation | |
Molecular basis for Epstein-Barr virus induced pathogenesis and disease | |
Mouse model of Epstein-Barr virus LMP1- and LMP2A-driven germinal center B-cell lymphoproliferative disease | |
The N-terminal half of EBNA2, except for seven prolines, is not essential for primary B-lymphocyte growth transformation. | |
Nasopharyngeal carcinoma super-enhancer-driven ETV6 correlates with prognosis | |
Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells | |
NF-kappaB inhibition in EBV-transformed lymphoblastoid cell lines | |
The NF-κB genomic landscape in lymphoblastoid B cells | |
Nonmuscle myosin heavy chain IIA mediates Epstein-Barr virus infection of nasopharyngeal epithelial cells | |
A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes | |
The nuclear chaperone nucleophosmin escorts an Epstein-Barr Virus nuclear antigen to establish transcriptional cascades for latent infection in human B cells | |
Nucleolin is important for Epstein-Barr virus nuclear antigen 1-mediated episome binding, maintenance, and transcription | |
Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein | |
NXP-2 association with SUMO-2 depends on lysines required for transcriptional repression | |
Oncogenic forms of NOTCH1 lacking either the primary binding site for RBP-Jkappa or nuclear localization sequences retain the ability to associate with RBP-Jkappa and activate transcription | |
The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential | |
Phenotypes of Epstein-Barr virus LMP1 deletion mutants indicate transmembrane and amino-terminal cytoplasmic domains necessary for effects in B-lymphoma cells | |
Protein kinase A associates with HA95 and affects transcriptional coactivation by Epstein-Barr virus nuclear proteins | |
Protein kinase N1, a cell inhibitor of Akt kinase, has a central role in quality control of germinal center formation | |
Reducing the complexity of the transforming Epstein-Barr virus genome to 64 kilobase pairs. | |
Repeat arrays in cellular DNA related to the Epstein-Barr virus IR3 repeat | |
Role of Ca2+/calmodulin-dependent kinase II-IRAK1 interaction in LMP1-induced NF-κB activation | |
Role of cellular tumor necrosis factor receptor-associated factors in NF-kappaB activation and lymphocyte transformation by herpesvirus Saimiri STP. | |
Roscovitine inhibits EBNA1 serine 393 phosphorylation, nuclear localization, transcription, and episome maintenance | |
A selectable marker allows investigation of a nontransforming Epstein-Barr virus mutant | |
Simple repeat sequence in Epstein-Barr virus DNA is transcribed in latent and productive infections | |
Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes. | |
The structural basis for the recognition of diverse receptor sequences by TRAF2 | |
Tumor necrosis factor receptor-associated factor (TRAF)-1, TRAF-2, and TRAF-3 interact in vivo with the CD30 cytoplasmic domain; TRAF-2 mediates CD30-induced nuclear factor kappa B activation. | |
U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2 | |
Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro | |
Viral perturbations of host networks reflect disease etiology | |
Virus and cell RNAs expressed during Epstein-Barr virus replication |